Drug firm Roche has launched Emicizumab under the brand name Hemlibra in India for preventive treatment of Hemophilia A.
Hemophilia A is an inherited disorder in which a person’s blood does not clot properly, leading to an uncontrolled and often spontaneous bleeding. It is the first weekly subcutaneous prophylaxis injection shown to prevent or reduce the frequency of bleeding episodes and improve the quality of life, Roche said in a statement.
All current prophylactic treatment options for people with Haemophilia A with factor VIII inhibitors require intravenous infusions several times a week. Even then, some people may experience bleeding joints which may lead to long-term damage.
Lara Bezerra, Chief Purpose Officer, Roche Pharma was reported as saying, “The introduction of Emicizumab (Hemlibra) is a significant milestone in the treatment of Hemophilia A in India and reaffirms our commitment to bring Roche’s ground breaking medicines to patients in India as early as possible.”
Bezerra added, “This breakthrough medicine represents a completely new way to manage Hemophilia A and redefines the standard of care.”
According to Roche Pharma, Hemlibra is approved by multiple regulatory authorities across the world and is now also approved and available in India.